Maximizing the Affinity, Specificity, & Efficacy of Oligonucleotide Therapeutics through Smarter Chemistry & Tissue- & Cell-Specific Delivery to Translate Innovation into Clinical Success
Oligonucleotide therapeutics are entering a defining moment. Once confined to rare genetic diseases, next-generation RNA modalities are now advancing into neurology, oncology and cardiometabolic disease. With breakthroughs in extrahepatic delivery and novel chemistries reshaping the development landscape, the opportunity is clear, unlock previously inaccessible targets and overcome limitations in therapeutic efficacy.
The 2nd Oligonucleotide-Based Therapeutics Summit is the definitive forum for a technical deep dive into the innovations transforming oligonucleotide drug development and unlocking the full therapeutic potential of this modality. Over three days, hear directly from the scientists engineering the next generation of extrahepatic and CNS delivery, spanning blood-brain barrier engineering, AI-designed miniproteins, novel conjugates, circular ASOs, and emerging chemistries such as saRNA. Through in-depth case studies and peer-led discussion, gain the insights needed to benchmark your delivery strategies, identify emerging platform opportunities, and avoid common translational pitfalls before they impact your programs. Connect with 70+ leaders across the oligonucleotide ecosystem to uncover practical solutions, exchange lessons learned and build valuable new partnerships. Leave equipped to make smarter development decisions, accelerate innovation, and bring transformative oligonucleotide therapies to patients faster.
What sets this summit apart: it's built specifically around delivery, chemistry and translation, not a broad RNA therapeutics showcase, but a focused, technical deep dive with the people solving these problems day to day, from Biogen and Avidity to City Therapeutics, Prime Medicine and beyond.
With entirely new, never-before-seen data on aptamers, breakthrough advances in endosomal escape, and emerging technologies expanding into oncology and metabolic disease, the 2nd Oligonucleotide-Based Therapeutics Summit is built for innovation. Attend to gain early access to the discoveries shaping the field, deepen your understanding of endosomal escape, and identify the technologies with the greatest therapeutic potential. Connect with the pioneers advancing next-generation oligonucleotide therapies, compare delivery strategies and de-risk your pipeline. This isn't a reflection on where the field has been, it's where the next chapter of oligonucleotide therapeutics is written.
Everything was perfect!
Apellis Pharmaceuticals
The meeting was great for networking; the panelists and presenters were all high caliber and the ensuing discussions very informative
Apellis Pharmaceuticals
The meeting was very interactive. The balance between the presentation and the roundtable discussion was really good. I learned a lot and made valuable connections as well
Fujifilm
All the talks were highly engaging and interesting. Good mix of science. Vendors were also interesting
GSK
It was great to hear from those in the field who have seen both the successes and failures and what they have learned from each
Triveni Bio
High-quality presentations and discussions, good time for discussions with colleagues and opportunities to meet new people
CMAP4 Therapeutics
Explore the Full Event Guide
- Get the full agenda, speaker line-up, and session breakdown for the Oligonucleotide Therapeutics Summit, and start planning which sessions on extrahepatic delivery, conjugate design, or next-gen chemistry are must-attends for your programme
- See the breadth of modalities and disease areas on the agenda, spanning metabolic, neurological, cardiovascular and oncology applications, and pinpoint where oligonucleotide technology could unlock your next target
- Meet the faculty shaping the field, from Directors of Oligonucleotide Chemistry to VPs of Platform Discovery and CSOs, with over half our confirmed speakers holding Director-level roles or above
- Check out sessions unveiling entirely new, never-before-seen data, including groundbreaking work on aptamers, before it's presented anywhere else
- See who else is in the room, from CMC leads to translational biology VPs across pharma and biotech, and start planning the conversations worth having before you arrive
Attending Companies Included
Explore Related Events
Explore the Agenda
Discover innovative oligonucleotide chemistry and delivery breakthroughs across our expert-led sessions, workshops, and panel discussions.
Partner With Us
Position your brand as a leading solution providers and expert at the heart of oligonucleotide drug development.
Join Oligonucleotide Experts
Connect with scientists and decision-makers driving the next generation of ASO and RNA-based therapeutics during dedicated networking sessions.